ProKidney Corp (OQ:PROK)

Business Focus: Biotechnology & Medical Research

May 21, 2024 07:00 am ET
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring...
May 10, 2024 07:00 am ET
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended...
Apr 10, 2024 07:00 am ET
Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies
Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies, which are now combined with their respective acquisition targets, have...
Mar 25, 2024 06:05 am ET
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced two recent strategic appointments enhancing the leadership team’s...
Mar 21, 2024 07:49 pm ET
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. “We are...
Feb 29, 2024 04:05 pm ET
ProKidney to Participate in Jefferies Biotech on the Bay Summit
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies...
Nov 30, 2023 06:05 am ET
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Nikhil Pereira-Kamath, MBA, Vice President of Business Development...
Nov 21, 2023 06:05 am ET
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients living with chronic kidney disease (CKD), today announced that management...
Nov 14, 2023 06:05 am ET
ProKidney Reports Third Quarter Financial Results
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. “Building off of...
Nov 13, 2023 05:02 pm ET
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced updated positive interim diabetic CKD data from its RMCL-002 Phase 2 study that...
Oct 30, 2023 04:12 pm ET
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present four posters discussing investigations into the...
Sep 05, 2023 06:05 am ET
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced that Dr. Tim...
Aug 10, 2023 04:10 pm ET
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second...
Jul 18, 2023 06:05 am ET
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced it has closed...
Jul 17, 2023 06:05 am ET
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Bruce Culleton, MD, as Executive Vice President,...
Jun 13, 2023 12:05 pm ET
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced its agreement...
Jun 01, 2023 04:05 pm ET
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in a...
May 11, 2023 04:01 pm ET
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the first quarter ended March 31, 2023, and...
May 04, 2023 06:05 am ET
ProKidney to Present at the BofA Securities Health Care Conference 2023
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the BofA Securities...
Mar 28, 2023 04:12 pm ET
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the fourth quarter ended December 31, 2022,...
Mar 03, 2023 06:05 am ET
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at TD Cowen’s 43rd Annual...
Jan 10, 2023 04:05 pm ET
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the publication of the trial design and early data analysis from REGEN-003, a Phase 2...
Dec 22, 2022 06:05 am ET
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st...
Nov 14, 2022 06:05 am ET
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2022,...
Nov 11, 2022 04:05 pm ET
ProKidney to Participate in Upcoming Investor Conferences
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following...
Nov 03, 2022 06:05 am ET
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chroni
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the allowance of the proact 1 (REGEN-006) Phase 3 study protocol for its...
Oct 14, 2022 12:00 pm ET
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters on REACT and CKD at the upcoming American...
Sep 23, 2022 06:15 am ET
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate...
Sep 08, 2022 06:05 am ET
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a...
Aug 31, 2022 06:05 am ET
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor...
Aug 11, 2022 05:30 pm ET
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III or “SCS”) (Nasdaq: PROK) (the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results of...
Aug 11, 2022 10:01 am ET
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced the appointments of John M. Maraganore, Ph.D. and...
Jul 20, 2022 08:00 am ET
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on Chronic Kidney Disease (CKD), announces the appointment of nephrologist Kerry Cooper, M.D. as Senior Vice...
Jul 12, 2022 08:00 am ET
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III
ProKidney LP (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on CKD, and Social Capital Suvretta Holdings Corp. III (“SCS”) (Nasdaq: DNAC), a special purpose acquisition company, today completed their previously...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.